R. Denton

发表

Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor

David W. Smith, J. Hendrick, T. Verdoorn, 2005, Journal of Pharmacology and Experimental Therapeutics.

Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists.

M. D. Hill, J. Macor, Yulia Benitex, 2017, ACS medicinal chemistry letters.

In Vitro–In Vivo Correlations in Drug Discovery and Development: Concepts and Applications in Toxicology

B. Car, K. Brannen, R. Denton, 2012 .

Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481

J. Macor, A. Mathur, M. Ahlijanian, 2019, ACS medicinal chemistry letters.

Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.

J. Macor, R. Schartman, G. Tong, 2012, Journal of medicinal chemistry.

Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.

J. Macor, R. Schartman, G. Thalody, 2013, Bioorganic & medicinal chemistry letters.

Estrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding.

N. Koszewski, R. Denton, A. Notides, 1992, The Journal of biological chemistry.

BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder.

J. Macor, A. Mathur, B. Srikumar, 2018, ACS medicinal chemistry letters.

Tricyclic Sulfones as Potent, Selective and Efficacious RORγt Inverse Agonists - Exploring C6 and C8 SAR Using Late-Stage Functionalization.

Michael G. Yang, D. Shuster, C. Weigelt, 2020, Bioorganic & medicinal chemistry letters.

A monoclonal antibody directed against an opiate binding site in rat neural membranes

J. Bidlack, R. Denton, 1984, Neuropeptides.

Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.

J. Macor, R. Schartman, G. Dubowchik, 2012, ACS medicinal chemistry letters.

The Classic Steroid Hormone Receptors and ERβ, the Novel Estrogen Receptor

R. Baron, S. Ghosh, R. Denton, 2000 .

A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.

Vijay T. Ahuja, J. Macor, Y. Shu, 2009, Journal of medicinal chemistry.

Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and effici

Kimberly A. Widmann, J. Macor, R. Schartman, 2008, Journal of medicinal chemistry.

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain

Alan G. E. Wilson, G. Shankar, S. Mandlekar, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.

Michael G. Yang, D. Shuster, C. Weigelt, 2021, ACS medicinal chemistry letters.

Differential autoregulation of glucocorticoid receptor expression in human T- and B-cell lines.

J. Harmon, R. Denton, L. Eisen, 1993, Endocrinology.

Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist.

D. Shuster, J. Macor, C. Weigelt, 2020, ACS medicinal chemistry letters.

A monoclonal antibody capable of modulating opioid binding to rat neural membranes.

J. Bidlack, R. Denton, 1985, The Journal of biological chemistry.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

J. Macor, Yulia Benitex, D. Post‐Munson, 2017, ACS medicinal chemistry letters.

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780

J. Macor, M. Ahlijanian, Joseph L. Cantone, 2014, International journal of Alzheimer's disease.

Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects

H. Soares, J. Macor, M. Ahlijanian, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat

H. Feldman, J. Macor, R. Berman, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.

G. Shankar, J. Macor, C. Albright, 2022, Journal of medicinal chemistry.

Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.

J. Hendrick, T. Verdoorn, D. Barten, 2005, The Journal of pharmacology and experimental therapeutics.

Discovery of (S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain.

Alan G. E. Wilson, G. Shankar, J. Macor, 2022, Journal of medicinal chemistry.

Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt ‒ Identification of a Potent, Selective Series with Biologic-Like In Vivo Efficacy.

K. McIntyre, D. Shuster, J. Macor, 2019, Journal of medicinal chemistry.

Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.

D. Shuster, J. Macor, C. Weigelt, 2020, ACS medicinal chemistry letters.

Generating monoclonal antibodies to the opioid receptor.

L. Harwell, J. Bidlack, R. Denton, 1983, Life sciences.

Discovery of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of adaptor protein 2-associated kinase 1 for the treatment of pain

A. Good, J. Macor, L. Bristow, 2023, Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents.

Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313.

Michael G. Yang, D. Shuster, C. Weigelt, 2021, Journal of medicinal chemistry.

JPET # 199356 3 Recommended section assignment to guide listing in table of contents : Neuropharmacology

H. Feldman, J. Macor, R. Berman, 2012 .

Inhibition of AAK 1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain s

Alan G. E. Wilson, Malley, G. Shankar, 2016 .

Synthesis of Functionalized Derivatives of the Gamma-Secretase Modulator BMS-932481 and Identification of its Major Metabolite.

Antonio Ramirez, J. Macor, M. Ahlijanian, 2020, Bioorganic & medicinal chemistry letters.

Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.

J. Macor, R. Schartman, G. Dubowchik, 2012, ACS medicinal chemistry letters.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

J. Macor, Yulia Benitex, D. Post‐Munson, 2017, ACS medicinal chemistry letters.